MIPSAGARGIN

Prostatic Neoplasms

GenSpera, Inc.Small moleculePhase 2Dormant

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

74 Active assets in the Prostatic Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Merck Sharp & Dohme LLC	Phase 4	BBB
Degarelix Novartis Pharmaceuticals	Phase 4	BBB
PREDNISONE TABLETS Merck Sharp & Dohme LLC	Phase 3	BBB
LEUPROLIDE Dana-Farber Cancer Institute	Phase 4	BB
Abiraterone Acetate Qilu Pharmaceutical Co., Ltd.	Phase 3	BB

View all 50 →

Same molecule, other indications

MIPSAGARGIN is also rated in:

adult hepatocellular carcinomaDormant

B

Indicative ·

57 / 100

nonpapillary renal cell carcinomaDormant

CCC

Indicative ·

54 / 100

prostate cancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.